|
| Press Releases |
|
 |
|
| Tuesday, August 27, 2024 |
|
|
First Results From Lexaria's Second GLP-1 Human Pilot Study |
| more info >> |
|
| Thursday, August 22, 2024 |
|
|
Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has received and can now report on 8-week body weight results from ongoing animal study WEIGHT-A24-1 (the "Study"). more info >> |
|
| Wednesday, August 21, 2024 |
|
|
Positive Interim Blood Sugar Results From Lexaria's GLP-1 Diabetes Animal Study |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has received 4-week and 8-week blood glucose results from ongoing animal study WEIGHT-A24-1 (the "Study"). more info >> |
|
| Monday, August 19, 2024 |
|
|
Positive Results from Lexaria's Molecular Characterization Study Monomeric form of GLP-1 drug preserved by DehydraTECH |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces positive findings from its applied research program together with the National Research Council of Canada ("NRC") that evaluated important mode of action facets of DehydraTECH processed with the glucagon-peptide 1 ("GLP-1") drug, semaglutide. more info >> |
|
| Monday, July 8, 2024 |
|
|
Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces three new patent awards. more info >> |
|
| Wednesday, May 8, 2024 |
|
|
Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that human pilot study #2, GLP-1-H24-2, (the "Study") is underway and the first dosing visit for all nine study participants has already concluded. more info >> |
|
| Monday, May 6, 2024 |
|
|
Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces an applied research program to evaluate certain molecular characteristics of DehydraTECH processed with the glucagon-peptide 1 ("GLP-1") drug, semaglutide, related to its mode of action and performance. more info >> |
|
| Tuesday, April 16, 2024 |
|
|
Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study |
| Lexaria Bioscience Corp. (Nasdaq: LEXX; LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces approval has been received from an independent third-party ethics review board, for human pilot study #2 (the "Study"), investigating GLP-1 drugs and DehydraTECH. more info >> |
|
| Tuesday, April 2, 2024 |
|
|
Lexaria Awarded New Patents |
| more info >> |
|
| Thursday, March 14, 2024 |
|
|
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer |
| Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the appointment of Nelson Cabatuan, CPA, as Chief Financial Officer (CFO) effective immediately. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Everest Medicines Announces China NMPA Approval of VELSIPITY(R) for Adults with Moderately to Severely Active Ulcerative Colitis
Feb 6, 2026 19:56 HKT/SGT
|
|
|
GIC Invests US$100M in Ascletis Pharma (1672. HK): Anchoring Long-Term Capital in China's Core Innovative Drug Assets
Feb 6, 2026 17:45 HKT/SGT
|
|
|
COSMOPlat Introduces Full-Stack AI to Hong Kong for Trillion-Dollar Industrial Digitalization
Feb 6, 2026 17:34: JST
|
|
|
GIC Private Limited initiated a stake in Ascletis Pharma (01672) by 64,128,000 shares at a price of HKD 12.18 per share
Feb 6, 2026 17:01 HKT/SGT
|
|
|
歌禮製藥-B（01672）獲新加坡政府投資公司首次入股 涉資約1億美元
Feb 6, 2026 16:56 HKT/SGT
|
|
|
歌礼制药-B（01672）获新加坡政府投资公司首次入股 涉资约1亿美元
Feb 6, 2026 16:50 HKT/SGT
|
|
|
COSMOPlat Introduces Full-Stack AI to Hong Kong for Trillion-Dollar Industrial Digitalization
Feb 6, 2026 16:34 HKT/SGT
|
|
|
トヨタ、役員人事を発表
Feb 6, 2026 16:00: JST
|
|
|
Everest Medicines Announces China NMPA Approval of VELSIPITY(R) for Adults with Moderately to Severely Active Ulcerative Colitis
Feb 6, 2026 15:17: JST
|
|
|
牧原股份港股上市：全球生豬养殖龍頭 價值成長兼具
Feb 6, 2026 15:08 HKT/SGT
|
|
|
牧原股份港股上市：全球生猪养殖龙头 价值成长兼具
Feb 6, 2026 15:01 HKT/SGT
|
|
|
優異供應鏈賦能與國際化佈局雙輪驅動 綠茶開啟高質量成長新篇章
Feb 6, 2026 14:47 HKT/SGT
|
|
|
优异供应链赋能与国际化布局双轮驱动 绿茶开启高质量成长新篇章
Feb 6, 2026 14:33 HKT/SGT
|
|
|
雲頂新耀維適平(R)獲中國國家藥品監督管理局批准上市 為中重度潰瘍性結腸炎治療提供新選擇
Feb 6, 2026 14:11 HKT/SGT
|
|
|
云顶新耀维适平(R)获中国国家药品监督管理局批准上市 为中重度溃疡性结肠炎治疗提供新选择
Feb 6, 2026 14:03 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
